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Background: Cytochrome P450 3A5 (CYP3A5) is an enzyme involved in the metabolism of many therapeutic drugs.
CYP3A5 expression levels vary between individuals and populations, and this contributes to adverse clinical
outcomes. Variable expression is largely attributed to four alleles, CYP3A5*1 (expresser allele); CYP3A5*3 (rs776746),
CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343) (low/non-expresser alleles). Little is known about CYP3A5
variability in Africa, a region with considerable genetic diversity. Here we used a multi-disciplinary approach to
characterize CYP3A5 variation in geographically and ethnically diverse populations from in and around Africa, and
infer the evolutionary processes that have shaped patterns of diversity in this gene. We genotyped 2538 individuals
from 36 diverse populations in and around Africa for common low/non-expresser CYP3A5 alleles, and re-sequenced
the CYP3A5 gene in five Ethiopian ethnic groups. We estimated the ages of low/non-expresser CYP3A5 alleles using
a linked microsatellite and assuming a step-wise mutation model of evolution. Finally, we examined a hypothesis
that CYP3A5 is important in salt retention adaptation by performing correlations with ecological data relating to
aridity for the present day, 10,000 and 50,000 years ago.
Results: We estimate that ~43% of individuals within our African dataset express CYP3A5, which is lower than previous
independent estimates for the region. We found significant intra-African variability in CYP3A5 expression phenotypes.
Within Africa the highest frequencies of high-activity alleles were observed in equatorial and Niger-Congo speaking
populations. Ethiopian allele frequencies were intermediate between those of other sub-Saharan African and non-African
groups. Re-sequencing of CYP3A5 identified few additional variants likely to affect CYP3A5 expression. We estimate the
ages of CYP3A5*3 as ~76,400 years and CYP3A5*6 as ~218,400 years. Finally we report that global CYP3A5 expression
levels correlated significantly with aridity measures for 10,000 [Spearmann’s Rho= −0.465, p=0.004] and 50,000 years ago
[Spearmann’s Rho= −0.379, p=0.02].
Conclusions: Significant intra-African diversity at the CYP3A5 gene is likely to contribute to multiple pharmacogenetic
profiles across the continent. Significant correlations between CYP3A5 expression phenotypes and aridity data are
consistent with a hypothesis that the enzyme is important in salt-retention adaptation.
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One of the main goals of the genomics revolution has
been to characterize diversity within indigenous popula-
tions, which have traditionally been under-represented
in research. The availability of genomic data is enabling
researchers to identify how and why genomic variation
affects individual and population differences in clinical* Correspondence: r.bains@ucl.ac.uk
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reproduction in any medium, provided the oroutcomes following pharmaceutical drug administration.
Additionally, evolutionary and demographic processes
which have shaped population variation at clinically rele-
vant regions of the human genome are now being deter-
mined. Studies of genes encoding drug metabolizing
enzymes, such as the Cytochrome P450 (CYP450) super-
family have identified variation which affects the safety
and efficacy of therapeutic drugs. However little is
known about intra-African variation at these loci. Africa
is heavily burdened with common and infectious dis-
eases [1], which are treated with multiple drugs. Studiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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olizing enzymes are likely to be beneficial to clinicians,
geneticists and researchers within the emerging field of
evolutionary medicine [2]. They are also likely to have
great potential for minimizing the risk of adverse clinical
outcomes in patients with recent African ancestry [3].
CYP3A enzymes, a sub-family of the CYP450 super-
family, are responsible for the phase I hepatic and intestinal
metabolism of a wide spectrum of endogenous and xeno-
biotic compounds [4]. The two most clinically relevant
CYP3A enzymes are CYP3A4 and CYP3A5, which together
are involved in the metabolism of ~50% of all therapeutic
drugs [5]. Because of the wide substrate range, some func-
tional variation in CYP3A genes is associated with individ-
ual and population differences in pharmacogenetic profiles
[6], adverse clinical outcomes [7], and elevated predispos-
ition to diseases [8,9].
There is considerable inter-ethnic variability in CYP3A5
expression levels [10]. Individuals tend to express CYP3A5
at high concentrations (21-202 pmol/mg) or have sig-
nificantly reduced, often undetectable, protein levels
(<21 pmol/mg) [11-13]. Variability in protein expression is
largely attributed to four CYP3A5 alleles; CYP3A5*1, an
expresser allele, and the low/non-expresser CYP3A5*3,
CYP3A5*6 and CYP3A5*7 alleles [13,14]. Studies have
reported that the highest frequencies of high-activity al-
leles are found in populations with recent African ancestry
[15,16]. CYP3A5*3 is the main determinant of CYP3A5
expression levels in populations outside Africa [10]. The
CYP3A5*6 and CYP3A5*7 alleles are observed almost ex-
clusively in individuals with recent African ancestry
[13-16], although CYP3A5*6 has been observed at low fre-
quency in a sample of individuals from Los Angeles with
Mexican ancestry, genotyped as part of the HapMap con-
sortium. CYP3A5*7 has been observed at a frequency of
3% in ethnic Koreans [17]. There is some uncertainty over
the functionality of the CYP3A5*6 mutation. Its effect on
protein expression was reported in 2001 [13]. One of two
cDNA products isolated from three CYP3A5*1/CYP3A5*6
heterozygotes did not contain the sequence for exon 7.
Subsequent western blot analyses of liver samples from
two CYP3A5*1/CYP3A5*6 heterozygotes found signifi-
cantly lower protein levels than in CYP3A5*1 homozy-
gotes. It has been proposed that CYP3A5*6 creates an
aberrant splicing pathway [13], however this has not been
confirmed experimentally. Although data presented by
Kuehl et al. suggest that CYP3A5 expression levels in
CYP3A5*6 carriers are lower than in CYP3A5*1 homozy-
gotes, in the absence of expression analysis and more
extensive in vivo and in vitro data we considered it pru-
dent to allow for the possibility that in at least some indi-
viduals CYP3A5*6 is expressed. Unlike the CYP3A5*3 and
CYP3A5*7 mutations, the association between CYP3A5*6
and clinical outcomes is not completely certain. A studyexamining the association between CYP3A genotypes and
the metabolism of midazolam found a significant associ-
ation between the metabolism of the drug and the pres-
ence of the CYP3A5*3 allele, but not the CYP3A5*6 allele
[18]. However, an independent study of Japanese breast
cancer patients found that tumor sizes were significantly
higher in women who carried the CYP3A5*6 allele [19].
Given this uncertainty we present analyses that assume
both that the CYP3A5*6 allele does, and does not affect
protein expression and function.
A previous study reported that elevated CYP3A5*3
frequencies are positively correlated with increased geo-
graphic distance from the equator [20]. There is a latitu-
dinal cline in the frequencies of alleles involved in heat
adaptation, and consequently hypertension susceptibility
[21]. A strong positive correlation is observed between
latitude and functionally important variants of genes
implicated in salt-sensitive hypertension, by regulating
cardiovascular reactivity and volume avidity, such as
angiotensinogen (AGT), G protein β3 subunit (GNB3),
and epithelial sodium channel γ (ENaCγ) [21]. CYP3A5 is
involved in the metabolism of renal cortisol to 6-β
-hydroxycortisol, a key regulator of renal sodium trans-
port, and immune responses which cause inflammation
[22]. It has been proposed that the expresser CYP3A5*1
allele provides a selective advantage in equatorial popula-
tions due to the role of CYP3A5 in salt retention and
the reabsorption of water [13,20]. Conversely, elevated
CYP3A5*1 frequencies are hypothesized to be detrimental
and are associated with elevated risk of salt-sensitive
hypertension in non-equatorial populations [8,23,24]. The
CYP3A5 gene region has high frequencies of derived,
functional alleles [25], and substantial population differen-
tiation in the frequencies of the CYP3A5*3 allele when
compared to neutral markers, as measured by weighted
FST tests, [26]. This suggests that low/non-expression of
CYP3A5 may be adaptive in non-equatorial populations.
Although CYP3A5 expression in Africa is likely to be
highly variable, few previous studies have characterized
intra-African diversity in CYP3A5 and other clinically
relevant genes. High levels of genetic diversity are ob-
served within the continent compared to other geo-
graphic regions, and this is consistent with a recent
African origin model of human evolution [27]. East
Africa is a particularly diverse region of the continent.
Reports have shown a gradual reduction in genetic
diversity with increased geographic distance from
Ethiopia [28-30] indicating that the region is one of the
most genetically diverse in the world. Studies of func-
tional variation in clinically relevant genes have found
significant inter-ethnic differences within Ethiopia and
between Ethiopian and other African populations
[31-33]. These data highlight the potential that focused
genetic studies of clinically relevant variation within
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African genetic diversity.
Within this study we have focused on characterizing
CYP3A5 variation in multiple geographically and ethnic-
ally diverse populations sampled from in and around
Africa. We focused on determining population structure
at this locus, and identified considerable population struc-
turing within Africa. These results suggest that there are
likely to be multiple pharmacogenetic profiles across
Africa which could affect the safety and efficacy of many
therapeutic drugs which are CYP3A5 substrates. Addition-
ally, we report correlations between CYP3A5 expression
phenotypes and aridity data for 10,000 and 50,000 years
ago, consistent with a previous hypothesis that the enzyme
is involved in salt retention/heat adaptation. This suggests
that global variability in expression phenotypes may have
occurred as a result of selective pressures on the gene.Results
The prevalence of clinically relevant CYP3A5 alleles in
Africa
We genotyped 2245 individuals from 32 geographically
and ethnically diverse African populations for common
clinically relevant CYP3A5 alleles. An additional 293
individuals from four non African populations from
Europe and the Arabian Peninsula were also genotyped
to permit comparisons of African diversity in a global
context (Table 1). Prior to our study, the distribution of
clinically relevant CYP3A5 alleles across Africa, and relative
to non-African populations, was unknown. We identified
CYP3A5*1, CYP3A5*3 and CYP3A5*6 in all genotyped
African population samples (allele frequency ranges: 4-81%,
4-81% and 4-33% respectively). CYP3A5*7 was confined al-
most exclusively to Niger-Congo speaking samples (range:
0-22%). The distribution of CYP3A5 alleles is structured by
major language family and geographic region, as evidenced
by Analysis of Molecular Variance [P<0.0001 for both
variables]. Pearson’s χ2 tests were carried out to examine
within-region differences. Considerable heterogeneity was
observed in East Africa [χ2=157.69, d.f.=21, p<0.0001]
and North Africa [χ2=37.61, d.f.=9, p<0.01] but not in
any other geographic region. The genotyped loci are in
complete LD (D´=1, p<0.0001), except between the
CYP3A5*6 and CYP3A5*1/*3 loci (D´=0.96, p<0.0001). A
low frequency recombinant haplotype was observed in 10
heterozygotes explaining why D´ between CYP3A5*1 and
CYP3A5*6 is not equal to 1. Haplotype analysis found that
the low/non-expresser CYP3A5 alleles occur predominantly
on independent haplotype backgrounds (Figure 1 and
Additional file 1 Table S1) suggesting that their convergent
effects on CYP3A5 expression are independent. A signifi-
cant correlation between pairwise genetic (FST) and geo-
graphic distances (kilometers) was observed using a Manteltest when all populations genotyped in this study (n=36)
were analyzed [Mantel r statistic=0.228, p<0.0001].
The geographic and ethnic distributions of low-,
intermediate- and high-expression phenotypes, based on
haplotype frequencies were inferred. Expresser phenotypes
were inferred assuming that CYP3A5*6 does and does not
cause a low/non-expression phenotype (Additional file 2
Figure S1 and Additional file 3 Figure S2 respectively). The
distributions in both Figures show that the highest fre-
quencies of high-activity phenotypes are in equatorial re-
gions of Africa, and Ethiopia has the highest within
country inter-ethnic diversity, which is driven by differ-
ences between the Anuak and other Ethiopian groups.
Correlations between ecological variables and inferred
CYP3A5 expression phenotypes
A previous study reported a strong positive correlation be-
tween CYP3A5*3 allele frequencies and latitude [20]. Lati-
tude is a correlate of multiple ecological variables that are
associated with functional markers of genes involved in
heat adaptation [21]. We tested for correlations between
frequencies of low/non-expresser CYP3A5 alleles, and in-
ferred expresser phenotypes, with latitude and the eco-
logical variables; temperature and precipitation (Table 2).
Additionally, we tested for correlations with aridity indices
calculated from temperature and precipitation data using
the de Martonne aridity index [34]. This enabled us to con-
sider the combined effect of temperature and precipitation
on CYP3A5 phenotypes. Correlations were estimated using
ecological data for the present day, and inferred for 10, 000
years ago (Holocene) and 50,000 years ago (Late Pleisto-
cene) (http://badc.nerc.ac.uk/home/index.html). Correla-
tions were performed assuming that CYP3A5*6 is a low/
non-expresser allele, and that it is a neutral allele.
Latitude correlated significantly with CYP3A5 expres-
sion in Africa [Spearmann’s Rho= −0.472, p=0.004], the
correlation remained significant when considering north
[Spearmann’s Rho= −0.659, p<0.0001] and south latitude
[Spearmann’s Rho= −0.701, p<0.0001] populations separ-
ately. Across a global cohort (87 populations) which,
included published genotyping data [20] and where
CYP3A5*3 alone is considered to predict CYP3A5 expres-
sion levels, a significant correlation between latitude and
frequencies of this allele was seen only for north latitude
populations [Spearmann’s Rho= 0.666, p<0.0001], but not
south [Spearmann’s Rho= 0.066, p=0.759]. No significant
correlation was observed between aridity values for the
present day and expresser phenotypes when CYP3A5*6
was considered a low/non expresser allele [Spearmann’s
Rho= −0.185, p=0.279] or a neutral allele [Spearmann’s
Rho= −0.0288, p=0.868]. Expresser phenotypes correlated
significantly with aridity values from the Holocene
[Spearmann’s Rho= −0.465, p=0.004] and Late Pleistocene
[Spearmann’s Rho= −0.379, p=0.02] when CYP3A5*6
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subsequently examined independent correlations between
expresser allele frequencies and temperature and precipi-
tation. We found significant correlations between ex-
presser allele frequencies and temperature for every time
period, both when CYP3A5*6 was considered to be a low/
non-expresser mutation and a neutral allele (p<0.0001 for
every correlation, see Table 2). No significant correlation
was observed between precipitation values and expresser
allele frequencies.
We subsequently examined the correlations between
present day ecological data and expresser allele frequen-
cies, while controlling for geographic distances between
populations, using partial Mantel tests. For each correl-
ation CYP3A5*6 was assumed to be a low/non-expresser
mutation. We found that the correlation between CYP3A5
expresser alleles and temperature remained significant
when controlling for geographic proximity between popu-
lations [Mantel r statistic=0.398, p=0.02]. However the
correlation with latitude was no longer significant [Mantel
r statistic=0.202, p=0.05].
CYP3A5 variation observed in Ethiopia
Previous studies of genetic variation in drug metabolizing
enzymes have identified considerable inter-ethnic diversity
within Ethiopia and between Ethiopian and other African
populations [31-33]. The results from our geographic sur-
vey of clinically relevant CYP3A5 variants also indicated
that there is considerable heterogeneity within Ethiopia,
and between Ethiopia and other African populations. We
performed a re-sequencing survey of the CYP3A5 gene in
five Ethiopian populations to characterize CYP3A5 diver-
sity in greater detail.
We observed significant inter-ethnic diversity in
CYP3A5 allele frequencies in Ethiopia. To identify add-
itional variation and elucidate intra-Ethiopian population
structure we re-sequenced an 8063bp region of CYP3A5,
which included the CYP3A5 promoter, exons and exon-
flanking introns, in five Ethiopian populations. 51 poly-
morphic sites were identified (Table 3). Nine (17.6%) were
exonic and, 3 out of 5 (6%) identified non-synonymous
polymorphisms were predicted to adversely alter protein
function. No significant difference in the proportion of
synonymous or non-synonymous variation was identified
by a codon-based Z-test [35] (Z=0.961 and p=0.169). The
proportion of amino acid changes that we observed at the
CYP3A5 gene (5 changes/502 codons= ~1%) is higher
than previously reported for 103 protein-coding genes
(147 changes/26,999 codons=0.56%) [36], although the dif-
ferences are not significant [paired t test, t=1.01, d.f.=1,
p=0.50]. We did not identify any variants in experimen-
tally established transcription factor binding sites [37,38].
Eight of the nine identified promoter variants occurred in
nucleotide positions that are highly conserved in primates(i.e. where the allele is the same in all primate species),
and bioinformatic analyses predicted that four out of nine
may affect transcription factor binding. Of all identified
polymorphisms – predicted and previously reported to
affect CYP3A5 expression and activity (n=10) – 4 (2 pro-
moter, CYP3A5*3 and CYP3A5*6) occurred at frequencies
over 1%. The highest frequency variants identified were
CYP3A5*3, CYP3A5*6 and the non-functional variant
rs15524, which is found in high LD with CYP3A5*3 [39].
Ethiopian CYP3A5 variation in the context of other
geographic populations
We analyzed the Ethiopian re-sequencing data along with
those previously reported for three ethnically diverse popu-
lations from the Corriell Repositories to analyze the data in
a global context [20] (Table 4). The results of the Hudson-
Kreitman-Aguadé (HKA) test [40], comparing intra- and
inter-species CYP3A5 diversity, was not significant
(p=0.6346). Tajima’s D, Li’s D* and F*, Fu and Li’s F and D
(using chimpanzee sequence to establish ancestral states),
and Fu’s FS all indicated a skew towards rare variants in
every population, which is consistent with general human
population growth or positive selection. Fu and Li’s D* and
F* reported a significant departure from neutrality for both
Europeans and the Anuak, although significance was only
reached for Europeans following Bonferonni correction (8
tests). Fu and Li’s FS reported a significant departure from
neutrality for 7 of the 8 populations after Bonferonni cor-
rection. Strobeck’s S results were consistent with Fu’s FS, as
expected. The results of the H test, used to assess whether
there is an excess of high frequency derived variants [41],
were not significant in any population (p>0.05), however
nucleotide diversity at CYP3A5 is low and this may be af-
fecting the tests.
72 haplotypes were inferred from allelic data for all 8
Ethiopian population samples, 33 (45.8%) containing
CYP3A5*1, 29 (40.3%) containing CYP3A5*3, 7 (9.7%)
containing CYP3A5*6, 1 (1.4%) containing CYP3A5*7,
and 2 (2.8%) containing both CYP3A5*3 and CYP3A5*6
(Additional file 4 Figures S3a and b). LD across the
gene is high. A phylogeny, based on network analysis of
the haplotype data, is presented in Figure 2. 98% of
European and 83% of Han Chinese haplotypes contain
the CYP3A5*3 allele, as do ~64% of Afar haplotypes and
~67% in both the Amhara and Oromo. Gene diversity is
highest in African Americans (0.963 ± 0.02) and lowest
in Europeans (0.589 ± 0.08). The CYP3A5*1 haplogroup
is significantly more diverse than the other haplogroups
(0.921 ± 0.01) (p<0.0001 for every comparison). Popula-
tion differentiation was measured by pairwise FST
(Table 5). The Afar, Amhara and Oromo are intermediate
between individuals with recent African ancestry and Han
Chinese and European groups. We placed population
structure seen at the CYP3A5 gene in a wider genomic
Table 1 Genotype and allele frequencies and tests for deviation from Hardy-Weinberg Equilibrium (χ2 p-values given)
Region Country Population CYP3A5*1/CYP3A5*3 CYP3A5*6 CYP3A5*7
AA AG GG Total G [*3] HWE GG GA AA Total A [*6] HWE −/− -/T T/T Total T [*7] HWE
Europe Armenia Southern Armenians 0 10 90 100 0.95 1.00 100 0 0 100 0.00 N/A 100 0 0 100 0.00 N/A
Turkey Anatolian Turks 2 10 62 74 0.91 0.11 74 0 0 74 0.00 N/A 74 0 0 74 0.00 N/A
Arabian Yemen Yemeni from Hadramaut 2 21 59 82 0.85 1.00 77 5 0 82 0.03 1.00 80 2 0 82 0.01 1.00
Peninsula Yemeni from Sena and Msila 7 17 13 37 0.58 0.74 29 7 1 37 0.12 0.42 35 2 0 37 0.03 1.00
North Africa Algeria Northern Algerians 9 42 108 159 0.81 0.12 146 15 0 161 0.05 1.00 159 2 0 161 0.01 1.00
Morocco Berbers 3 28 54 85 0.80 1.00 79 7 0 86 0.04 1.00 85 1 0 86 0.01 1.00
Sudan Northern Sudanese 24 58 51 133 0.60 0.29 104 28 0 132 0.11 0.36 135 1 0 136 0.00 1.00
Sudanese from Kordofan 11 11 8 30 0.45 0.16 19 10 1 30 0.20 1.00 29 1 0 30 0.02 N/A
East Africa Ethiopia Afar 10 31 32 73 0.65 0.61 47 26 0 73 0.18 0.11 73 0 0 73 0.00 N/A
Amhara 14 22 40 76 0.67 0.004 55 19 2 76 0.15 0.67 76 0 0 76 0.00 N/A
Anuak 38 32 6 76 0.29 1.00 44 25 7 76 0.26 0.23 75 1 0 76 0.01 1.00
Maale 20 36 19 75 0.49 0.82 53 22 0 75 0.15 0.34 74 1 0 75 0.01 1.00
Oromo 12 28 34 74 0.65 0.20 55 19 1 75 0.14 1.00 75 0 0 75 0.00 N/A
Republic of South Sudan Southern Sudanese 74 42 9 125 0.24 0.46 58 50 15 123 0.33 0.42 117 8 0 125 0.03 1.00
Tanzania Chagga 28 18 4 50 0.26 0.71 36 14 0 50 0.14 0.57 41 9 0 50 0.09 1.00
Uganda Bantu speakers from Ssese 36 3 0 39 0.04 1.00 22 17 0 39 0.22 0.16 23 16 0 39 0.21 0.31
West Africa Ghana Asante 27 8 0 35 0.11 1.00 20 13 1 34 0.22 1.00 29 5 0 34 0.07 1.00
Bulsa 58 29 3 90 0.19 1.00 61 28 0 89 0.16 0.11 69 19 2 90 0.13 0.62
Kasena 28 17 2 47 0.22 1.00 31 16 0 47 0.17 0.32 35 12 0 47 0.13 1.00
Senegal Manjak 57 29 4 90 0.21 1.00 59 24 9 92 0.23 0.02 81 13 0 94 0.07 1.00
Wolof 55 31 8 94 0.25 0.27 58 31 1 90 0.18 0.29 78 15 1 94 0.09 0.55
West Central Cameroon Kotoko 18 21 0 39 0.27 0.04 23 16 1 40 0.23 0.65 36 4 0 40 0.05 1.00
Africa Shewa Arabs 26 31 12 69 0.40 0.62 42 24 3 69 0.22 1.00 60 9 0 69 0.07 1.00
Mayo Darle 66 38 13 117 0.27 0.06 71 33 13 117 0.25 0.01 102 15 0 117 0.06 1.00
Somie, Cameroonian Grassfields 36 28 1 65 0.23 0.16 44 19 2 65 0.18 1.00 52 13 0 65 0.10 1.00
Congo Congolese from Brazzaville 35 18 2 55 0.20 1.00 43 11 1 55 0.12 0.55 45 10 0 55 0.09 1.00
Nigeria Igbo 64 23 0 87 0.13 0.35 60 24 4 88 0.18 0.47 73 12 2 87 0.09 0.14
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Table 1 Genotype and allele frequencies and tests for deviation from Hardy-Weinberg Equilibrium (χ2 p-values given) (Continued)
South East Malawi Chewa 66 25 1 92 0.15 1.00 66 23 3 92 0.16 0.69 60 31 0 91 0.17 0.06
Africa Lomwe 13 4 1 18 0.17 N/A 10 8 0 18 0.22 N/A 14 4 0 18 0.11 N/A
Ngoni 15 2 1 18 0.11 N/A 9 6 3 18 0.33 N/A 16 2 0 18 0.06 N/A
Tumbuka 44 18 0 62 0.15 0.34 40 17 5 62 0.22 0.14 45 17 0 62 0.14 0.59
Yao 37 18 1 56 0.18 0.67 43 12 1 56 0.13 1.00 46 10 0 56 0.09 1.00
Mozambique Sena 58 21 3 82 0.16 0.44 51 28 5 84 0.23 0.75 59 25 1 85 0.16 0.68
South Africa Bantu speakers 22 17 2 41 0.26 1.00 29 9 3 41 0.18 0.10 34 4 2 40 0.10 0.03
Zimbabwe Lemba 17 6 0 23 0.13 1.00 13 10 1 24 0.25 1.00 17 7 0 24 0.15 1.00
Zimbabweans from Mposi 36 7 4 47 0.16 0.008 36 10 3 49 0.16 0.09 34 16 2 52 0.19 1.00
HWE could not be calculated for the Lomwe and Ngoni as both populations had fewer than 50 chromosomes meaning that the test had insufficient power. No population deviated from Hardy-Weinberg equilibrium,
following Bonferonni correction (for CYP3A5*3: adjusted p value = 0.00139; correction for 36 tests, for CYP3A5*6: adjusted p value=0.0015; correction for 34 tests, for CYP3A5*7: adjusted p value=0.0017; correction for
30 tests). Deviations from HWE cannot be calculated for monomorphic loci: labeled “N/A” on the Table. “Total” refers to the number of individuals, from a given population, successfully genotyped at each locus.
Population refers to the grouping of individuals either by self-declared ethnicity or geography/place collected.
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markers on the non-recombining regions of the Y chromo-
some (NRY) and the mitochondrial genome (hypervariable
region 1 [HVS1] and coding region SNPs) [42]. We com-
pared Ethiopian NRY and HVS1 genotypes with data for
92 Fars from Iran, 95 Nigerian Igbo, 126 Greek-Cypriots
and 60 Halfawi from the Republic of Sudan. The Anuak
are outliers compared to the other Ethiopian populations
(data not shown), consistent with genome wide-markers
[43] and what we report for CYP3A5. Intra-Ethiopian
population structure at the CYP3A5 gene is also consistent
with that seen at other drug metabolizing genes CYP1A2
[31], and UGT1A1 [32].Estimating the age of clinically relevant CYP3A5 alleles
The age of an allele is the time since it arose by mutation
[44,45]. Estimating the ages of CYP3A5 alleles may help to
identify specific demographic processes which have af-
fected inter-population differences in allele frequencies, or
identify an important role for natural selection in selecting
for specific alleles [44]. Under the stepwise mutation
model of microsatellite evolution, and assuming no re-
combination, we estimated the time to the most recent an-
cestor (TMRCA) of the CYP3A5*3 mutation to be 2388
generations (95% confidence intervals [C.I.]: 1797–3211)
and CYP3A5*6 to be 6825 generations (95% C.I.: 3086–
11,975). Assuming that a generation is 32 years [46], the
estimated age of the CYP3A5*3 mutation is ~76,416 years
(95% C.I. 57,504-102,752 years) and CYP3A5*6 is 218,400
years (95% C.I. 98,752-383,200 years) (Table 6). Our esti-
mates of the age of CYP3A5*3 is consistent with its pres-
ence within and outside of Africa. The distribution of the
CYP3A5*6 allele shows some similarity to that of FMO2*1,
an allele of the gene encoding the drug metabolizing en-
zyme FMO2 [33]. FM02*1 occurs at similar frequencies
across Africa and is not found at high frequencies outside
of the continent. The estimated age of FMO2*1 is 502,404
years (95% C.I. 154,790–1,041,243 years) based on a co-
alescent simulation [47] and using data from populations
re-sequenced as part of the NIEHS SNPs database (http://
egp.gs.washington.edu/). The age estimates of both the
CYP3A5*6 and FMO2*1 alleles predate estimates of the
range-expansion of modern humans out of Africa.Discussion
We performed an extensive geographic survey of clinic-
ally relevant CYP3A5 alleles in a large African cohort
and found highly variable frequencies of the ancestral
CYP3A5*1 allele (9-96%) across the continent. We esti-
mate that ~43% of individuals within our African dataset
express CYP3A5, which is much lower than all other
previous estimates for the continent (between 55-95%)
[15,16]. The classification of CYP3A5 alleles as expresseror low/non-expresser will affect estimates of expresser
frequencies in Africa. In vitro studies of CYP3A5 expres-
sion levels in CYP3A5*6 homozygotes are needed to es-
tablish the effect of the mutation on protein expression.
The results from such studies may alter the classification
of CYP3A5*6 as a clinically relevant CYP3A5 allele, and
mean that CYP3A5 protein expression levels across
Africa are likely to be consistent with those presented in
Additional file 3 Figure S2 . Our estimates of the propor-
tion of CYP3A5 expressers differ across Africa, consist-
ent with the Sahara acting as a barrier to gene flow
[48,49]. Additionally, we estimate that the proportion of
CYP3A5 expressers in East Africa (~36%) is lower than
in other regions of sub-Saharan Africa (~45%), and re-
port considerable heterogeneity among Ethiopian ethnic
groups (17-54%). We found that the highest frequencies
of inferred high-activity phenotypes were seen in equa-
torial and Niger-Congo speaking populations.
From the geographic survey we observed that the
Ethiopian allele frequencies are intermediate between sub-
Saharan African and Eurasian groups [50]. Our study has
extended previous work on CYP3A5 in Ethiopia [51] by
accounting for, and identifying, considerable inter-ethnic
variability within the country. CYP3A5 haplotype diversity
and structure in the Afar, Amhara and Oromo were char-
acteristic of that seen in European Caucasians and Han
Chinese individuals. There is a known Arabian contribu-
tion to Ethiopian ancestry as a result of migration of Sem-
itic groups into the region, which has influenced genetic
diversity [48,52]. We further examined intra-Ethiopian di-
versity at mitochondrial and Y-chromosome genetic
markers and found that the Anuak were outliers. This sug-
gests that the intra-Ethiopian diversity we observed can
be explained by Arabian admixture in the Afar, Amhara
and Oromo, rather than differential selection pressures
on CYP3A5.
Considerable intra-African population structuring at the
CYP3A5 gene suggests that there are likely to be multiple
pharmacogenetics profiles for key drugs used across the
continent, including many used in the treatment and con-
trol of malaria [53] and HIV-1 [54]. We identified signifi-
cant differences between Ethiopians and other sub-Saharan
African populations, and intra-Ethiopian diversity, at the
CYP3A5 gene. The results from our study suggest that East
Africans are likely to be distinct from a wider cohort of
African patients, and that there are likely to be inter-ethnic
differences within East Africa. The results from large sur-
veys [32,33], including our study, emphasize the import-
ance of including sub-Saharan African populations in
pharmacogenetics research; over 90% of the global disease
burden is found in developing countries [55,56]. An appre-
ciable number of the diseases found within the region are
treated with CYP3A5 substrates [5,57] at doses optimized
for patients with recent European ancestry [26]. Larger and
Figure 1 The distribution of the five inferred CYP3A5 haplotypes across the dataset. The size of each circle is proportional to the number
of individuals sampled from a given population (see Additional file 1 Table S1). The allele combinations at all three loci are given in the key. The
alleles in brackets define the inferred haplotype. N.B. the recombinant CYP3A5 haplotype 5: *3/*6, is observed at low frequency in the dataset.
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Table 2 Correlation analyses, between ecological variables and CYP3A5 allelic and inferred expression data
Time period Ecological variable N=87 N=36
CYP3A5*3 CYP3A5*6 CYP3A5*7 High expresser allele
(assuming CYP3A5*6
is a low/non-
expresser allele)
Low expresser allele
(assuming CYP3A5*6
is a low/non-expresser
allele)
High expresser allele
(assuming CYP3A5*6 is
not a low/non-
expresser allele)
Low expresser allele
(assuming CYP3A5*6
is not a low/non-
expresser allele)
Rho P-value Rho P-value Rho P-value Rho P-value Rho P-value Rho P-value Rho P-value
Latitude 0.706 <0.0001 −0.331 0.048 −0.177 0.303 −0.472 0.004 0.472 0.004 −0.416 0.012 0.416 0.012
North latitude 0.666 <0.0001 −0.621 0.001 −0.410 0.047 −0.659 <0.0001 0.659 <0.0001 −0.620 0.001 0.620 0.001
South latitude 0.066 0.759 0.318 0.130 0.122 0.571 −0.701 <0.0001 0.701 <0.0001 −0.370 0.075 0.370 0.075
Temperature −0.664 <0.0001 0.268 0.114 0.494 0.002 0.655 <0.0001 −0.655 <0.0001 0.627 <0.0001 −0.627 <0.0001
Present Day Precipitation −0.129 0.232 −0.290 0.867 −0.150 0.384 −0.028 0.869 0.028 0.869 0.113 0.511 −0.113 0.511
Aridity 0.286 0.007 −0.201 0.24 −0.267 0.116 −0.185 0.279 0.185 0.279 −0.029 0.868 0.029 0.868
Temperature −0.597 <0.0001 0.216 0.207 0.342 0.041 0.560 0.0004 −0.560 0.0003 0.635 <0.0001 −0.635 <0.0001
Holocene Precipitation 0.072 0.510 −0.235 0.167 −0.522 0.001 −0.381 0.022 0.381 0.022 −0.190 0.266 0.190 0.266
Aridity 0.471 <0.0001 −0.344 0.04 −0.575 0.0002 −0.465 0.004 0.465 0.004 −0.293 0.083 0.293 0.0832
Temperature −0.644 <0.0001 0.297 0.079 0.608 <0.0001 0.649 <0.0001 −0.649 <0.0001 0.641 <0.0001 −0.641 <0.0001
Late Pleistocene Precipitation 0.160 0.139 −0.238 0.163 −0.353 0.035 −0.204 0.233 0.204 0.233 −0.023 0.892 0.023 0.892
Aridity 0.532 <0.0001 −0.436 0.008 −0.480 0.003 −0.379 0.026 0.379 0.023 −0.211 0.216 0.211 0.216
For analyses with inferred CYP3A5 expression phenotypes high-, intermediate- and low- expression diplotypes were counted as genotypes and the frequencies of expresser and low/non-expresser alleles calculated.
For analyses with phenotypes, CYP3A5*6 was considered to cause low/non-expression and to have no effect on CYP3A5 expression. Significant p-values, at the 5% level, are shown in bold. Rho indicates Spearmann’s
Rho. “N” refers to the number of populations analyzed for each CYP3A5 allele. For CYP3A5*3 frequencies, African data were combined with those previously reported [20]. For CYP3A5*6 and CYP3A5*7 correlations, only
African data genotyped for this study were tested. North latitude and south latitude correlations were only performed with populations genotyped for this study.
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Table 3 All polymorphic sites identified in an 8063bp CYP3A5 region re-sequenced in five Ethiopian populations
Afar Amhara Anuak Maale Oromo Total
Region of CYP3A5 Position on
chromosome 7
Position relative to the translation
initiation codon (A of ATG is +1)
dbSNP database refSNP ID Effect f n f n f n f n f n f n
Promoter 99278314 −795 T>A rs3823812 0.00 3 0.00 3 0.01 4 0.01 10 0.01 5 0.0331 25
Promoter 99278267 −748 C>G 0.01 5 0.00 2 0.00 1 0.00 1 0.01 6 0.0198 15
Promoter 99278224 −705 3 base pair deletion 0.00 1 0.00 1 0.01 5 0.00 1 0.00 3 0.0146 11
Promoter 99278223 −704 A>G 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1
Promoter 99278152 −633 C>A 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1
Promoter 99278146 −627 G>A 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Promoter 99278144 −625 A>G 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1
Promoter 99278070 −551 C>A rs28365079 0.01 4 0.01 5 0.02 15 0.01 8 0.01 4 0.0476 36
Promoter 99277988 −469 G>A 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1
UTR of exon 1 99277593 −74 C>T rs28371764 0.00 2 0.01 6 0.00 0 0.00 2 0.00 2 0.0158 12
UTR of exon 1 99277544 −25 A>C 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1
Intron 1 99277392 127 G>A 0.00 0 0.00 0 0.00 1 0.00 2 0.00 0 0.0040 3
Intron 1 99277337 182 C>A 0.00 0 0.00 0 0.00 3 0.00 0 0.00 0 0.0040 3
Intron 2 99272310 5209 C>T rs28365067 0.01 11 0.02 12 0.01 5 0.01 8 0.01 8 0.0580 44
Intron 2 99272290 5229 G>A rs41301652 0.00 0 0.00 0 0.00 2 0.00 0 0.00 0 0.0026 2
Intron 2 99272275 5244 C>T 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0026 2
Intron 3 99272103 5416 C>T 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0026 2
Intron 3 99272009 5510 T>A rs28969392 0.01 6 0.01 4 0.01 10 0.01 9 0.00 3 0.0422 32
Intron 3 99271928 5591 C>T rs41301655 0.00 0 0.01 4 0.00 1 0.00 0 0.00 2 0.0092 7
Intron 3 99271853 5666 A>G rs41301658 0.00 1 0.00 1 0.00 3 0.01 7 0.00 2 0.0185 14
Intron 3 99271808 5711 A>G rs41258334 0.01 11 0.01 11 0.01 5 0.01 9 0.01 8 0.0580 44
Intron 3 99271778 5741 A>G 0.01 6 0.00 3 0.01 4 0.01 8 0.00 3 0.0317 24
Intron 3 99270539 6980 A>G rs776746 Defines the
variant CYP3A5*3
0.13 95 0.14 102 0.06 44 0.10 75 0.13 97 0.5581 413
Intron 3 99270504 7015 3 base pair deletion 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0014 1
Intron 3 99270318 7201 C>T rs8175345 0.00 0 0.00 1 0.01 9 0.00 0 0.00 1 0.0149 11
Exon 4 99270249 7270 G>A G77S 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0014 1
Intron 4 99270164 7355 C>T rs28365074 0.00 0 0.00 0 0.00 1 0.00 0 0.00 2 0.0041 3
Intron 5 99264352 13167 T>C rs68178885 0.00 3 0.00 2 0.00 1 0.00 3 0.00 1 0.0132 10
Intron 6 99264149 13370 G>A rs41301670 0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0027 2
Exon 7 99262835 14684 G>A rs10264272 Defines the
variant CYP3A5*6
0.04 28 0.03 23 0.05 39 0.03 23 0.03 21 0.1763 134
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Table 3 All polymorphic sites identified in an 8063bp CYP3A5 region re-sequenced in five Ethiopian populations (Continued)
Exon 7 99262793 14726 A>G rs2838372 Synonymous 0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.0013 1
Intron 7 99262642 14877 A>G 0.00 1 0.01 5 0.02 12 0.01 9 0.00 2 0.0382 29
Intron 7 99261737 15782 T>C rs28969393 0.01 5 0.01 4 0.01 9 0.01 9 0.00 3 0.0396 30
Exon 8 99261651 15868 A>G K266R 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Intron 8 99261583 15936 C>A 0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2
Intron 8 99260546 16973 G>A 0.00 0 0.00 1 0.00 0 0.00 0 0.00 0 0.0013 1
Exon 9 99260502 17017 C>T R268Stop 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Intron 9 99260407 17112 C>T rs28383478 0.00 0 0.00 2 0.00 0 0.00 0 0.00 0 0.0026 2
Intron 9 99260362 17157 G>T rs4646453 0.00 3 0.00 3 0.01 4 0.01 10 0.01 5 0.0331 25
Intron 9 99260282 17237 T>G 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Intron 9 99260170 17349 T>G 0.00 3 0.00 2 0.01 7 0.01 7 0.00 3 0.0291 22
Intron 9 99258524 18995 C>T rs10247580 0.00 0 0.00 2 0.02 12 0.01 7 0.00 1 0.0291 22
Intron 9 99258320 19199 G>A 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Intron 9 99258316 19203 T>C 0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2
Exon 10 99258124 19395 A>C K342T 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1
Exon 11 99250397 27125-27126 T insertion rs41303343 Defines the
variant CYP3A5*7
0.00 0 0.00 0 0.00 1 0.00 1 0.00 0 0.0026 2
Exon 11 99250381 27138 A>G V350M 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1
Intron 12 99247647 29872 G>T 0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2
Intron 12 99247503 30016 1 base pair deletion rs28365093 0.00 3 0.01 4 0.02 15 0.01 8 0.01 4 0.0450 34
Intron 12 99246026 31493 T>C rs28365069 0.01 4 0.01 11 0.01 11 0.02 18 0.01 9 0.0699 53
3' UTR 99245914 31605 C>T rs15524 0.14 105 0.14 109 0.09 69 0.11 84 0.14 107 0.6253 474
n refers to the total number of chromosomes on which a particular variant was observed. f is the relative frequency of each variant. Total refers to the number of times a variant was observed in the Ethiopian cohort
(758 chromosomes) and f is its relative frequency. Position on chromosome 7 is based on NCBI Build 132, February 2009.
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diverse African populations will improve our understand-
ing of how specific drugs and dosages contribute to ad-
verse clinical outcomes within Africa and the African
Diaspora. The number of such studies will undoubtedly in-
crease with the availability of newer and cheaper sequen-
cing technologies [58,59] and progression towards the
$1000 genome [60].
We combined our African CYP3A5*3 data with those
previously published to examine the global prevalence of
the allele. We found a significant, positive correlation
between CYP3A5*3 allele frequencies and latitude, con-
sistent with a previous report [20]. This correlation
remained significant when only African data were con-
sidered [Spearmann Rho= 0.666, p<0.0001]. In contrast
we found no significant correlation between latitude and
CYP3A5*6 or CYP3A5*7 frequencies. Given the re-
stricted geographic distribution of the CYP3A5*6 allele
mainly to Africa, coupled with our estimates of its age
(>200,000 years), it is possible that this allele was lost in
a population bottleneck during the range-expansion of
humans out of Africa. The heterogeneous distribution of
CYP3A5*7 in Africa suggests that it arose from a much
more recent mutation event and may have spread with the
expansion of Niger-Congo speaking populations ~4000
years ago [61]. Nonetheless, the reasons why the derived
CYP3A5*3, CYP3A5*6 and CYP3A5*7 alleles are found at
appreciable frequencies in sub-Saharan Africa remains un-
known, and the possibility of independent evolutionary
causes cannot be discounted. The global distribution of
the CYP3A5*3 allele is unusual when compared with
microsatellite markers, genotyped in samples from the
Human Genome Diversity Panel (HDGP-CEPH) [20]. In-
tegrated haplotype scores (iHS) for CYP3A5*3 haplotypes
in HGDP-CEPH populations sampled from high latitudes
north and south of the equator are outliers in the iHSTable 4 A summary of the tests for departures from neutralit
Global populations
African-Americans Europeans Han Ch
Sample size 23 24 23
Nucleotide diversity (π) 5.4 x 10-4 9 x 10-5 1.1 x 10
McDonald-Kreitman test 0.475 0.50 0.777
Tajima’s D −1.04 −1.92 −1.21
Fu and Li’s D* −0.97 −2.86 −1.82
Fu and Li’s F* −1.17 −3.00 −1.91
Fu and Li’s D −0.64 −1.37 −1.45
Fu and Li’s F −0.92 −1.81 −1.55
Fu’s FS −31.06 −5.71 −1.54
Strobeck’s S 1.00 0.999 0.929
Fay and Wu’s H statistic −0.13140 −3.25532 −1.893
Statistically significant departures from neutrality, following Bonferonni correction (genome-wide distribution (iHS≥2) [62]. iHS scores of
CYP3A5*3 haplotypes are similar to those of genomic re-
gions surrounding the LCT (lactase) and CD36 genes [63],
which have both been reported to have undergone positive
selection [64-66]. It is plausible that an increase in latitude
of ~20°, when humans first expanded from East Africa to
the Arabian Peninsula, is coupled with specific environ-
mental changes which provided a novel selection pressure.
Temperature and precipitation data associated with the
Quaternary QUEST project (accessed through the British
Atmospheric Centre: http://badc.nerc.ac.uk/home/index.
html) suggest that changes in precipitation over the past
50,000 years are greater than those in temperature. How-
ever we did not find any significant correlation between
precipitation values and CYP3A5 allele frequencies. We
did observe negative correlations between inferred expres-
sion phenotypes (assuming CYP3A5*6 is a low/non-ex-
presser allele) and aridity values for the Holocene
[Spearmann’s Rho= −0.465, p=0.004] and Late Pleistocene
[Spearmann’s Rho= −0.379, p=0.02]. Under the de
Martonne aridity index, this means that high frequencies
of high-activity alleles are positively correlated with arid
and semi-arid environments [34]. This finding is consistent
with the hypothesis that high-activity CYP3A5 alleles may
be adaptive in regions where there are frequent water short-
ages, by aiding the rapid retention of water [20]. However,
stronger correlations were found with temperature alone.
Although further work will be needed to confirm these eco-
logical correlations, the strong correlation with temperature
is consistent with what we would expect for functional vari-
ation of genes involved in heat adaptation [21]. However,
we cannot rule out that there may be an, as yet untested,
ecological variable which may have provided a selective
pressure.
We have provided the first estimate of the age of the
CYP3A5*3 allele as ~76,000 years (95% C.I. 57,504-y for an 8063bp region of CYP3A5
Ethiopian populations
inese Afar Amhara Anuak Maale Oromo
75 76 76 76 76
-4 2.1 x 10-4 2.5 x 10-4 3.6 x 10-4 3.5 x 10-4 2.2 x 10-4
0.462 0.475 0.576 1.00 0.777
−1.46 −1.13 −1.26 −0.96 −1.79
−1.19 0.12 −2.72 −0.11 −1.05
−1.54 −0.43 −2.57 −0.53 −1.58
−1.56 −0.08 −1.93 0.73 −0.96
−1.79 −0.52 −1.96 0.13 −1.48
−9.48 −11.74 −18.44 −11.08 −22.84
1.00 1.00 1.00 1.00 1.00
72 0.10774 −0.23998 −0.47177 −0.87086 −1.75514
correction for 8 tests; adjusted p≤0.00625) are shown in bold.
Figure 2 A network of all CYP3A5 haplotypes inferred for Ethiopians and Coriell populations. Networks assume single mutational steps.
Haplotypes are colored according to the haplogroup to which they belong; haplotypes which are defined by the CYP3A5*3 allele are shown in
red; those defined by CYP3A5*1 in yellow; CYP3A5*7 in green; CYP3A5*6 in blue and CYP3A5*3/*6 recombinant haplotypes are shown in purple.
The size of each haplotype is proportional to its frequency in the global database. Additional file 4 Figure S3a contains information on the exact
composition of each coded haplotype.
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estimate is consistent with the wide geographic distribu-
tion of CYP3A5*3, both inside and outside Africa although
not with the low haplotype diversity [20,67] and high iHS
scores [62] previously reported. This may be because
the allele age estimation presented here was made using
Ethiopian data whereas the previously reported low haplo-
type diversity [20,67] and high iHS scores [62] were based
on non-African samples. It is also possible that the
microsatellite mutation rate for rs10536492 differs from
the genome wide average for dinucleotide repeats [68],
which would influence the age estimates, or that the ex-
tensive LD on haplotypes containing CYP3A5*3 is
explained by unusually low recombination rates in that
genomic region. Finally, while the correlations between
the CYP3A5*3 geographic distribution and ecologicalvariables relating to temperature and aridity, as well as
previously reported low haplotype diversity [20,67] and
high iHS scores [62], both independently support the
hypothesis that the CYP3A5*3 allele is adaptive, alterna-
tive targets of positive selection on the same haplotype
background may exist and both they (if present) and the
CYP3A5*3 allele may have been differentially selected
inside and outside Africa.
Conclusions
The data that we present complement and extend work
in previous publications which reported evidence of geo-
graphically restricted positive selection on the CYP3A5
gene [20,25,26,69]. In addition to improved knowledge
of the effect and distribution of clinically relevant gen-
etic variation, our approach highlights the importance of
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tionary approaches in clinical research. Evolutionary
approaches to genetic studies are likely to identify add-
itional populations that require targeted health interven-
tions. Further studies which characterize variation in
medically important genes in ethnically and geographic-
ally diverse global populations are needed as we progress
towards personalized clinical medicine, a key goal of the
genomics revolution [70].Methods
Samples
The DNA samples analyzed in this study were part of a col-
lection at The Centre for Genetic Anthropology at Univer-
sity College London. Samples were collected anonymously
and with informed consent (verbal in Africa) from osten-
sibly healthy individuals, between 1998–2007, from speci-
fied locations in and around Africa [ethical approval:
UCLH 99/0196]. Additional ethical approval was obtained
for Ethiopian collections from the National Health
Research Ethical Clearance Committee under the Ethiopian
Science and Technology Commission in Addis Ababa.
All samples have been previously used in studies on clinic-
ally relevant genes [31-33]. For analyses, individuals
were grouped by the collection location or by ethnicity
(Additional file 5 Table S2). Samples were not grouped
according to country as the partitioning of much of the
African continent by colonial powers was recent and largely
irrespective of ethnic identities [71]. 1028 CYP3A5*1/*3
genotypes for 51 global populations, from the Human
Genome Diversity Panel-Centre d’Etude du Polymorphisme
Humain (HGDP-CEPH) collection, which had previously
been published [20] were combined with the 2538 sample
cohort genotyped for this study. CYP3A5 re-sequencing
data, which were previously published, for 70 individuals
from three distinct ethnic groups from the Coriell Reposi-
tories (24 European Caucasians, 23 African-Americans
and 23 Han Chinese individuals) were combined with the
Ethiopian cohort for detailed integrative analyses [20].Table 5 Pairwise FST values for five Ethiopian populations and
Afar Amhara Anuak Maale
Afar * 0.74597 <0.00001 0.00436
Amhara −0.00248 * <0.00001 0.00347
Anuak 0.04566 0.05138 * 0.00257
Maale 0.01951 0.01736 0.01061 *
Oromo −0.00255 −0.0036 0.04981 0.01547
African-Americans 0.08997 0.09366 0.01558 0.03432
Europeans 0.04873 0.03807 0.15448 0.08716
Han Chinese 0.10812 0.0893 0.23763 0.16215
Pairwise FST values are shown in the bottom left side of the Table, the correspondin
significant after Bonferroni correction (adjusted p-value = 0.00625; correction for 8Published data were provided by Dr Emma Thompson
from the University of Chicago.
Genotyping and re-sequencing
Genotyping of clinically relevant CYP3A5 alleles; Genotyp-
ing of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7
was performed using TaqMAN allelic discrimination
technology [ABiosystems product code: C_26201809_30
for CYP3A5*1/*3, and ABiosystems product code:
C_30203959 for CYP3A5*6], and KASPar (performed ex-
ternally by KBiosciences®, UK).
Re-sequencing of CYP3A5; The 13 exons and their
flanking introns, promoter region and 3´ untranslated of
CYP3A5 were amplified in 379 Ethiopian individuals using
primers designed on the basis of the CYP3A5 reference se-
quence in NCBI Build 132 [(http://www.ncbi.nlm.nih.gov/)
(see Additional file 6 Table S3 for a list of primers)].
Amplicons were sequenced using ABI PRISM Dye Termi-
nators version 3.1 on an ABI 96-capillary 3730×l DNA
Analyzer according to the manufacturer’s protocol (Applied
Biosystems, Applera, UK). Part of the CYP3A5 gene was re-
sequenced externally by Macrogen®, USA.
Microsatellite genotyping; A –GT microsatellite, lo-
cated ~1500 base pairs downstream of the 3´ end of
CYP3A5 was genotyped in 379 Ethiopian individuals, for
whom re-sequencing data were also generated. Microsatel-
lite genotyping was performed using a high-throughput
method adapted from [72]. A 456 base pair region of
CYP3A5, approximately ~1000 base pairs downstream of
the 3´ UTR was amplified using the forward primer 5´-
AATATATGTGTTTGTATGTGTG-3´ and a fluorescently
labeled reverse primer FAM-AAGTGCTACCAATTTTGT
ACGT-3´. PCR amplification was performed in 10 μl reac-
tion volumes containing 1ng of template DNA, 0.5 μM of
primers, 0.2 units Taq DNA polymerase (HT Biotech,
Cambridge, UK), 0.2 μmol dNTPs, 0.1 μmol of 10X Buffer
IV (Thermo ScientificW) and 0.28 μl of magnesium chloride
(concentration 25 mM). Cycling conditions were 5 minutes
of pre-incubation at 95°C, followed by 38 cycles of 95°C for
one minute, 58°C for 40 seconds, 72°C for 40 seconds, withthree other global populations
Oromo African-Americans Europeans Han Chinese
0.76537 <0.00001 <0.00001 <0.00001
0.93525 <0.00001 <0.00001 <0.00001
<0.00001 <0.00001 <0.00001 <0.00001
0.00267 <0.00001 <0.00001 <0.00001
* <0.00001 <0.00001 <0.00001
0.08803 * <0.00001 <0.00001
0.03371 0.19028 * 0.00257
0.09715 0.29154 0.0677 *
g p-values are shown in the top right of the Table. P-values which are
tests) are shown in bold.
Table 6 Age estimates of clinically relevant CYP3A5 variants
CYP3A5
variant
Location on
chromosome 7
Location
in gene
Allele
dated
Number of
chromosomes
Average
squared
distance
(ASD)
Time to most recent
common ancestor
95% confidence intervals of allele age
estimate based on a star phylogeny
Estimate of
allele age
Lower Upper
Generations Years Generations Years Generations Years
CYP3A5*3 99270539 Intron 3 G 134 1.0746 2388 76,416 1797 57,504 3211 102,752
CYP3A5*6 99262835 Exon 7 A 18 3.0714 6825 218,400 3086 98.752 11975 383,200
rs15524 99245914 3´ UTR T 324 1.8426 4095 131,040 3157 101,024 5413 173,216
Allele ages were estimated using a mutation rate of 0.00045 and a generation time of 32 years. The confidence intervals for the estimated age of the CYP3A5*6
are large; most likely a reflection of the small sample size. UTR is the Untranslated Region.
Bains et al. BMC Genetics 2013, 14:34 Page 15 of 18
http://www.biomedcentral.com/1471-2156/14/34a final elongation step at 72°C for 10 minutes. Following
amplification, a 1.1 μl aliquot of amplified PCR product
was added to 9.89 μl of high purity (HiDi) formamide and
0.11 μl of ROX-500 size standard (Applied Biosystems,
Warrington, UK). Samples were run on an ×3730 DNA
Analyzer and analyzed using GeneMapper 4 software
(Applied Biosystems, Warrington UK).
Data analyses
Molecular diversity and Population genetics; exact tests
of deviation from Hardy-Weinberg equilibrium (using
10,000 steps in a Markov chain), pairwise FST, and
AMOVA, were all performed using Arlequin 3.5 [73].
Pairwise FST estimates were used to perform principal
co-ordinates analysis in the R-programming environ-
ment using routines in the APE package. The D´measure
of linkage disequilibrium was calculated using the expect-
ation maximization algorithm using LDMax (part of the
GOLD software package, freely available at: http://www.
sph.umich.edu/csg/abecasis/GOLD/docs/ldmax.html).
Haplotypes were inferred using PHASE version 2.1 (1000
iterations, 500 burn-in) [74]. Singletons were removed for
haplotype and LD analysis. Haplotype networks were
constructed using a median-joining network implemented
in Network 4.6.1 and re-colored using Adobe PhotoShop
CS4. Nucleotide diversity, tests for departures from neutral-
ity, Fay and Wu’s H test and the HKA test were all
performed using DnaSP 5.0 [75]. The chimpanzee CYP3A5
gene sequence was downloaded from NCBI (http://www.
ncbi.nlm.nih.gov/).
Ecological correlations; geographic co-ordinates were
used to calculate distance from the equator (in kilome-
ters) using the online programme: http://www.movable-
type.co.uk/scripts/latlong.html. Raw ecological data for
temperature (in degrees Celsius) and precipitation (in
mm), at each set of geographic co-ordinates, for 0,
10,000 and 50,000 years ago were extracted from the
British Atmospheric Data Centre (http://badc.nerc.ac.
uk/home/index.html), from the ALL-5G datasetassociated with the Quaternary QUEST (http://
researchpages.net/QQ/) [76]. The data were extracted
using Python. The raw data have a resolution of 5 de-
grees latitude and 7.5 degrees longitude and were inter-
polated to a resolution of 1 degree latitude and 1 degree
longitude. The interpolations were done using the
smooth.2d function in the fields library of the R-
programming environment. An estimate of relative aridity
was inferred from extracted temperature and precipitation
values corresponding to each geographic location using the
de Martonne aridity index [34]. Mantel and partial Mantel
tests were performed in the R-programming environment
using routines in the APE package [77] and ecodist pack-
age [78] respectively.
Bioinformatics analyses of genetic variation on protein
expression and function; cross-species alignments of
CYP3A5 orthologues (sequences obtained from NCBI:
http://www.ncbi.nlm.nih.gov/) were performed using
ClustalW software (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Analyses of regulatory motifs in the CYP3A5
promoter were performed using MatInspector [79], ef-
fects of amino acid substitutions on the structure and
function of CYP3A5 were performed using PolyPhen2
[80], predictions of mutations which are likely to affect
gene splicing were performed using the online Berkeley
Drosophila Genome Project splice predictor [81].
Estimating the age of the clinically relevant CYP3A5
variants; The gametic phase of CYP3A5 mutations and
the –GT microsatellite (rs10536492) was not determined
empirically. Allele ages were estimated using data for in-
dividuals homozygous for particular haplotypes. As no
Ethiopian individual was identified to be a CYP3A5*7
homozygote, this variant could not be dated. Under the
stepwise mutation model the variance (ASD) in the
microsatellite repeat length, from the most recent com-
mon ancestor, is a linear function of the mutation rate
(μ) and coalescence time in generations (t); ASD=μt
[82,83]. A mutation rate of 4.5×10-4 was used to estimate
the time to the most recent common ancestor (MRCA)
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nucleotide microsatellites in the human genome [68,84].
ASD and t were calculated using Ytime software [85].
The microsatellite length of the ancestral MRCA is
assumed to be known. For this study the ancestral length
of the microsatellite was estimated to be 35; as the
majority of CYP3A5*1 haplotypes had 35 repeats.
Confidence intervals for the age estimates were obtained
from calculating the distances between the ancestral and
derived chromosomes under a star-genealogy model;
based on the results of network analysis of CYP3A5 hap-
lotypes. A generation was assumed to be 32 years [46].
Additional files
Additional file 1: Table S1.“The proportion of each inferred CYP3A5
haplotype observed in each population.” The Table lists the frequencies
of each inferred CYP3A5 haplotype, by population.
Additional file 2: Figure S1. “The distribution of high-, intermediate-
and low- CYP3A5 expression phenotypes, inferred from diplotypes.” The
Figure shows inferred CYP3A5 expression phenotypes, assuming that
CYP3A5*6 causes low/non-expression of CYP3A5. The size of each circle is
proportional to the number of individuals sampled from a given
population (see Additional file Table S1).
Additional file 3: Figure S2. “The distribution of high-, intermediate-
and low- CYP3A5 expression phenotypes, inferred from diplotypes.” The
Figure shows inferred CYP3A5 expression phenotypes, assuming that
CYP3A5*6 does not cause low/non-expression of CYP3A5. The size of
each circle is proportional to the number of individuals sampled from a
given population (see Additional file Table S1).
Additional file 4: Figures S3a and b. “Haplotypes inferred from
genotype data in 8 populations.” Supplementary Figure 3a shows the
composition of each CYP3A5 haplotype inferred from genotype data for
8 global populations. The frequencies of each haplotype, by population,
are shown in Additional file Figure S3b.
Additional file 5: Table S2. “Geographic co-ordinates, sample size and
major language family of each population genotyped in the geographic
survey of clinically relevant CYP3A5 alleles. The CYP3A5 gene was re-
sequenced in five Ethiopian populations.” This Table provides details of
all populations which were genotyped, and re-sequenced for this study.
Additional file 6: Table S3. “A list of the primers used for PCR
amplification and sequencing of CYP3A5.”
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